TET2 and acute myeloid leukemia: Accordingly, in FLT3-ITD AML without TET2 mutations only long-term LIC with a FLT3-ITD/WT ratio >0.78 were effectively targeted by creno while leukemic progenitors with a ratio <0.78 were not sensitive (Figure 5).